MX9605660A - Formulaciones liquidas orales de alendronato. - Google Patents
Formulaciones liquidas orales de alendronato.Info
- Publication number
- MX9605660A MX9605660A MX9605660A MX9605660A MX9605660A MX 9605660 A MX9605660 A MX 9605660A MX 9605660 A MX9605660 A MX 9605660A MX 9605660 A MX9605660 A MX 9605660A MX 9605660 A MX9605660 A MX 9605660A
- Authority
- MX
- Mexico
- Prior art keywords
- oral liquid
- alendronate
- alendronate formulations
- formulations
- liquid alendronate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describe un protocolo de terapia para tratar y para evitar el deteriorooseo en pacientes que tienen dificultad para deglutir, por medio de administrar una formulacion líquida de alendronato que se puede diglutir fácilmente. También se describen formas farmacéuticamente de dosis de un jarabe, una solucion acuosa, una solucion formada de un polvo reconstituido, de alendronato, para llevar a cabo el método terapéutico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08245289 | 1994-05-17 | ||
US08/245,289 US5462932A (en) | 1994-05-17 | 1994-05-17 | Oral liquid alendronate formulations |
PCT/US1995/005926 WO1995031203A1 (en) | 1994-05-17 | 1995-05-12 | Oral liquid alendronate formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MXPA96005660A MXPA96005660A (es) | 1998-02-01 |
MX9605660A true MX9605660A (es) | 1998-02-28 |
Family
ID=22926074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9605660A MX9605660A (es) | 1994-05-17 | 1995-05-12 | Formulaciones liquidas orales de alendronato. |
Country Status (34)
Country | Link |
---|---|
US (1) | US5462932A (es) |
EP (1) | EP0759757B1 (es) |
JP (1) | JP4111536B2 (es) |
KR (1) | KR100372966B1 (es) |
CN (1) | CN1079672C (es) |
AT (1) | ATE222495T1 (es) |
AU (1) | AU691634B2 (es) |
CA (1) | CA2190148C (es) |
CO (1) | CO4600739A1 (es) |
CY (1) | CY2336B1 (es) |
CZ (1) | CZ285860B6 (es) |
DE (1) | DE69527842T2 (es) |
DK (1) | DK0759757T3 (es) |
DZ (1) | DZ1884A1 (es) |
ES (1) | ES2180646T3 (es) |
FI (1) | FI118296B (es) |
HK (1) | HK1009245A1 (es) |
HR (1) | HRP950293B1 (es) |
HU (1) | HU220626B1 (es) |
IL (1) | IL113651A (es) |
MX (1) | MX9605660A (es) |
MY (1) | MY112285A (es) |
NO (1) | NO310179B1 (es) |
NZ (1) | NZ289231A (es) |
PL (1) | PL179634B1 (es) |
PT (1) | PT759757E (es) |
RU (1) | RU2176507C2 (es) |
SI (1) | SI0759757T1 (es) |
SK (1) | SK281098B6 (es) |
TW (1) | TW402501B (es) |
UA (1) | UA29505C2 (es) |
WO (1) | WO1995031203A1 (es) |
YU (1) | YU49354B (es) |
ZA (1) | ZA953960B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
EA000347B1 (ru) * | 1995-02-17 | 1999-04-29 | Мерк Энд Ко., Инк. | Способ уменьшения риска невертебральных переломов костей |
CA2219354A1 (en) * | 1995-05-12 | 1996-11-14 | Merck & Co., Inc. | Prevention of tooth loss by the administration of alendronate or its salts |
IL118422A0 (en) * | 1995-06-02 | 1996-09-12 | Merck & Co Inc | Use of alendronate for the prevention of osteoporosis |
AU703887B2 (en) * | 1995-06-06 | 1999-04-01 | Merck & Co., Inc. | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
US6100301A (en) * | 1996-02-28 | 2000-08-08 | Pfizer Inc | Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists |
IL120270A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
EP1007054A4 (en) * | 1996-10-04 | 2000-07-19 | Merck & Co Inc | LIQUID ALENDRONATE FORMULATIONS |
US6376477B2 (en) | 1996-11-25 | 2002-04-23 | Merck & Co., Inc. | Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism |
US6080779A (en) * | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
US6376476B1 (en) * | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
FI104901B (fi) | 1997-10-20 | 2000-04-28 | Leiras Oy | Uudet metyleenibisfosfonihappojohdannaiset |
GB9802617D0 (en) * | 1998-02-07 | 1998-04-01 | Knoll Ag | Pharmaceutical formulation |
US6331533B1 (en) | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
US6194469B1 (en) * | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
CN1372468A (zh) * | 1999-06-02 | 2002-10-02 | 宝洁公司 | 羟乙磷酸二钠口服制剂 |
US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
US7008640B2 (en) | 2000-07-17 | 2006-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral use with improved absorption |
WO2002058708A1 (en) * | 2001-01-23 | 2002-08-01 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
US8197561B2 (en) | 2001-10-10 | 2012-06-12 | River Basin Energy, Inc. | Process for drying coal |
US7695535B2 (en) | 2001-10-10 | 2010-04-13 | River Basin Energy, Inc. | Process for in-situ passivation of partially-dried coal |
US7537622B2 (en) * | 2001-10-10 | 2009-05-26 | Fmi Newcoal, Inc. | Process for drying coal |
CA2468687A1 (en) * | 2001-12-13 | 2003-06-26 | Merck & Co., Inc. | Liquid bisphosphonate formulations for bone disorders |
PL371264A1 (en) * | 2001-12-21 | 2005-06-13 | The Procter & Gamble Company | Method for the treatment of bone disorders |
DK1880744T3 (en) * | 2002-05-10 | 2015-02-09 | Hoffmann La Roche | Bisphosphonic acids for the treatment and prevention of osteoporosis |
ITTO20020406A1 (it) * | 2002-05-13 | 2003-11-13 | Chiesi Farma Spa | Formulazioni di bisfosfonati ad uso iniettabile. |
US7041309B2 (en) * | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
GR1004331B (el) * | 2002-10-07 | 2003-09-05 | Verisfield (Uk) Ltd | Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος |
PT1790347E (pt) * | 2002-12-20 | 2015-02-05 | Hoffmann La Roche | Formulação de ibandronato a dose elevada |
US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
SI1753395T1 (sl) * | 2004-05-24 | 2011-01-31 | Warner Chilcott Co Llc | Enterične trdne formulacije oralnih odmerkov bifosfonata, ki vsebuje kelirno sredstvo |
US20080287400A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645460B2 (en) * | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
US20080286359A1 (en) * | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
EP1761270A1 (en) * | 2004-06-23 | 2007-03-14 | Merck & Co., Inc. | Estrogen receptor modulators |
AU2005275193A1 (en) * | 2004-07-15 | 2006-02-23 | Nanobac Life Sciences | Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses |
WO2006020009A1 (en) * | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
WO2006039721A2 (en) * | 2004-10-08 | 2006-04-13 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
WO2008128056A1 (en) * | 2004-10-08 | 2008-10-23 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps |
US20060134190A1 (en) * | 2004-12-16 | 2006-06-22 | Banner Pharmacaps Inc. | Formulations of bisphosphonate drugs with improved bioavailability |
US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
JP2009530414A (ja) * | 2006-03-17 | 2009-08-27 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | ビスホスホネート化合物及び方法 |
ES2361333T3 (es) * | 2006-09-04 | 2011-06-16 | Gador S.A. | Composición líquida para la prevención y/o el tratamiento de diferentes enfermedades metabólicas óseas, usos de la misma, y procedimiento para la preparación de la misma. |
KR20090083326A (ko) * | 2006-11-21 | 2009-08-03 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비스포스포네이트 흡입 제제와 그 사용 방법 |
US8974801B2 (en) * | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
US20090170815A1 (en) * | 2007-12-28 | 2009-07-02 | Roxane Laboratories Incorporated. | Alendronate oral liquid formulations |
WO2009100107A2 (en) * | 2008-02-05 | 2009-08-13 | Actavis Group Ptc Ehf | Alendronate formulations, method of making and method of use thereof |
US20100034752A1 (en) * | 2008-08-11 | 2010-02-11 | Toru Hibi | Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same |
US9057037B2 (en) | 2010-04-20 | 2015-06-16 | River Basin Energy, Inc. | Post torrefaction biomass pelletization |
US8956426B2 (en) | 2010-04-20 | 2015-02-17 | River Basin Energy, Inc. | Method of drying biomass |
US9889225B2 (en) * | 2010-08-20 | 2018-02-13 | Kaohsiung Medical University | Method for bone formation by administering poly(lactic-co-glycolic acid) cross-linked alendronate |
PT2648702T (pt) | 2010-12-06 | 2019-03-29 | Effrx Pharmaceuticals Sa | Formulações de bifosfonatos efervescentes estáveis com caracteristicas de rápida solubilização |
CN103070824B (zh) * | 2013-01-24 | 2014-07-16 | 天津红日药业股份有限公司 | 一种含有伊班膦酸钠的注射液 |
WO2015054429A1 (en) * | 2013-10-08 | 2015-04-16 | Innopharma, Inc | Aprepitant oral liquid formulations |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1187828B (it) * | 1985-05-24 | 1987-12-23 | Gentili Ist Spa | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi |
GB8618259D0 (en) * | 1986-07-25 | 1986-09-03 | Leo Pharm Prod Ltd | Pharmaceutical compositions |
DE3822650A1 (de) * | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
FI83421C (fi) * | 1989-06-21 | 1991-07-10 | Huhtamaeki Oy | Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat. |
US5227506A (en) * | 1989-09-06 | 1993-07-13 | Merck & Co., Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
US5356887A (en) * | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
CA2035179C (en) * | 1990-01-31 | 2001-08-14 | Gerald S. Brenner | Pharmaceutical compositions containing insoluble salts of bisphosphonic acids |
US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
FR2703590B1 (fr) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
-
1994
- 1994-05-17 US US08/245,289 patent/US5462932A/en not_active Expired - Lifetime
-
1995
- 1995-05-08 IL IL11365195A patent/IL113651A/xx not_active IP Right Cessation
- 1995-05-09 TW TW084104572A patent/TW402501B/zh not_active IP Right Cessation
- 1995-05-11 MY MYPI95001236A patent/MY112285A/en unknown
- 1995-05-12 DK DK95924570T patent/DK0759757T3/da active
- 1995-05-12 PL PL95320614A patent/PL179634B1/pl not_active IP Right Cessation
- 1995-05-12 ES ES95924570T patent/ES2180646T3/es not_active Expired - Lifetime
- 1995-05-12 SK SK1477-96A patent/SK281098B6/sk unknown
- 1995-05-12 UA UA96124659A patent/UA29505C2/uk unknown
- 1995-05-12 CA CA002190148A patent/CA2190148C/en not_active Expired - Fee Related
- 1995-05-12 RU RU96123917/14A patent/RU2176507C2/ru not_active IP Right Cessation
- 1995-05-12 NZ NZ289231A patent/NZ289231A/en unknown
- 1995-05-12 WO PCT/US1995/005926 patent/WO1995031203A1/en active IP Right Grant
- 1995-05-12 AU AU29010/95A patent/AU691634B2/en not_active Expired
- 1995-05-12 DE DE69527842T patent/DE69527842T2/de not_active Expired - Lifetime
- 1995-05-12 HU HU9603162A patent/HU220626B1/hu not_active IP Right Cessation
- 1995-05-12 AT AT95924570T patent/ATE222495T1/de active
- 1995-05-12 MX MX9605660A patent/MX9605660A/es unknown
- 1995-05-12 EP EP95924570A patent/EP0759757B1/en not_active Expired - Lifetime
- 1995-05-12 JP JP52977395A patent/JP4111536B2/ja not_active Expired - Fee Related
- 1995-05-12 KR KR1019960706447A patent/KR100372966B1/ko not_active IP Right Cessation
- 1995-05-12 PT PT95924570T patent/PT759757E/pt unknown
- 1995-05-12 CZ CZ963367A patent/CZ285860B6/cs not_active IP Right Cessation
- 1995-05-12 CN CN95193086A patent/CN1079672C/zh not_active Expired - Fee Related
- 1995-05-12 SI SI9530610T patent/SI0759757T1/xx unknown
- 1995-05-16 HR HR950293A patent/HRP950293B1/xx not_active IP Right Cessation
- 1995-05-16 ZA ZA953960A patent/ZA953960B/xx unknown
- 1995-05-16 DZ DZ950055A patent/DZ1884A1/fr active
- 1995-05-16 CO CO95020682A patent/CO4600739A1/es unknown
- 1995-05-17 YU YU31795A patent/YU49354B/sh unknown
-
1996
- 1996-11-15 NO NO19964864A patent/NO310179B1/no not_active IP Right Cessation
- 1996-11-15 FI FI964593A patent/FI118296B/fi not_active IP Right Cessation
-
1998
- 1998-08-12 HK HK98109860A patent/HK1009245A1/xx not_active IP Right Cessation
-
2003
- 2003-03-03 CY CY0300019A patent/CY2336B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2336B1 (en) | Oral liquid alendronate formulations. | |
HK1050313A1 (en) | Oral transmucosal drug dosage using solid solution | |
NZ503946A (en) | Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments | |
YU48583B (sh) | Postupak za pripremanje formulacije u obliku pilule za oralno davanje | |
CA2390377A1 (en) | Method and apparatus for delivery of controlled doses of therapeutic drugs in endoluminal procedures | |
PL338982A1 (en) | Drug for improving duration of muscle action or for treating muscular disorders or diseases | |
ATE289199T1 (de) | Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten | |
WO1999040883A3 (en) | Compositions and methods for the treatment of cystic fibrosis | |
RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
CA2180178A1 (en) | Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis | |
MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
EE04330B1 (et) | Levosimendani transmukoossed koostised ja nende kasutamine ravimi valmistamiseks | |
TW200517119A (en) | Method of treatment using interferon-tau | |
EG17992A (en) | Preparation of a medicament for arthritis and theumatism | |
HUP9900521A2 (hu) | Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására | |
RU98118897A (ru) | Способ увеличения массы костной ткани при переломах | |
PT95867A (pt) | Processo para a preparacao de uma composicao de libertacao retardada compreendendo um copolimero de lactide e glicolide, para tratamento de doencas periodonticas |